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within the four questions. Respondents were willing to sacrifice median 5 and 
8 years of their remaining lifespan until the age of 80 years for avoiding two 
migraines per month and per week, respectively. Mean utilities for two migraines 
each month were U20m= 0.84 (SD 0.26) and U80m= 0.89 (SD 0.14), and for each 
week were U20w= 0.79 (SD 0.27) and U80w= 0.83 (SD 0.17), respectively. Self-reported 
migraneurs elicited higher mean utilities compared to non-migraneurs for all 
migraine health states but this difference was statistically significant only for 
U80m (p= 0.039). Also, males attached lower mean utilities for all health states 
than females but this was significant only for U80m (p= 0.018). Besides, older 
respondents valued higher mean utilities for U20m compared to the younger ones 
(p= 0.040). ConClusions: Our findings provide the first time trade-off utilities 
on migraine associated HRQOL impairment. Disutility caused by migraine ranged 
between 0.1 and 0.2 depending on attack frequency.
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HumaNistic ReseaRcH OutcOmes iN multiPle scleROsis: Review Of tHe 
liteRatuRe fROm latiN ameRica
Einarson T.R.1, Bereza B.1, Machado M.2
1University of Toronto, Toronto, ON, Canada, 2Biogen Idec, São Paulo, Brazil
objeCtives: This research reviews the research literature reporting humanistic 
outcomes related to multiple sclerosis (MS) in Latin America. Methods: We con-
ducted a systematic search of Medline, Embase, LILACS and Scielo from inception 
through 2013 for articles reporting original research on quality of life (QoL), utility 
scores for states of MS, patient preference, mental health, social and emotional 
wellbeing in people with MS in Latin America. Adherence and related issues were 
not included. Outcomes were categorized into: mental domain (cognitive function; 
mental health), physical domain (mobility/independence; fatigue; restless legs syn-
drome), employment, QoL, caregiver burden, and patient preference. Results: A 
total of 38 studies were selected for analysis. Among them, 23 addressed issues in 
the mental domain (9 cognitive functions and 14 mental health), 41 in the physical 
domain (24 mobility/physical function, 15 fatigue and 2 restless legs syndrome). 
One addressed impact of MS on employment, 16 QoL, 2 caregiver burden and 1 
patient preference. Researchers used 56 different instruments to collect their data 
from 2286 patients. Compared with controls, MS patients had significantly (P< 0.05) 
lower levels of functioning, cognition and increased presence of mental illness. All 
of these factors were significantly associated with decreased QoL in patients (odds 
ratios ranged from 4.2-10.1; P< 0.05). Similarly, fatigue and restless legs syndrome 
correlated significantly with anxiety, depression and level of mobility/functioning as 
well as QoL. ConClusions: As in other parts of the world, MS exerts a substantial 
negative impact on the lives of people with MS in Latin America. It lowers their QoL 
and interferes with their ability to move about, care for themselves and work. Their 
social life is also negatively affected. The amount of literature on this subject is 
quite limited. More research in Latin America is needed to understand humanistic 
outcomes in these patients and management of their MS.
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tHe effect Of iNsOmNia aND iNsOmNia tReatmeNt siDe effects ON 
HealtH status, wORk PRODuctivity, aND HealtH caRe ResOuRce use
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objeCtives: The aims of this study were to quantify the burden of insomnia and 
to quantify the association between side effects of insomnia medications and 
health outcomes. Methods: Data from the 2013 US (N= 75,000) and 5EU (N= 62,000) 
National Health and Wellness Survey (NHWS) were used. The NHWS is a patient-
reported survey administered to a demographically representative sample of adults 
(with respect to age, sex, race/ethnicity, and region). Those who met DSM-V criteria 
for insomnia and, separately, those treated with insomnia were compared with their 
respective propensity score-matched control groups on health status (SF-36v2), work 
productivity (WPAI-GH), and health care resource use using ANOVA tests. Among 
those with treated insomnia, those with and without side effects were compared on 
health outcomes using general linear models controlling for demographics, health 
history, and comorbidities. Results: Compared with their respective matched con-
trol groups, patients with insomnia (n= 4147) and treated insomnia (n= 2860) in the 
5EU reported significantly worse mean health utilities (0.60 vs. 0.74; 0.60 vs. 0.74, 
respectively), greater overall work impairment (38.74% vs. 14.86%; 39.50% vs. 15.66%), 
and more annual physician visits (9.10 vs. 4.08; 9.58 vs. 4.11). Similar findings were 
observed in the US cohort. Among those treated for insomnia, 13.56% and 24.55% 
in the US and 5EU, respectively, were non-adherent due to side effects. In the US, 
this behavior was associated with significantly worse health utilities (0.60 vs. 0.64) 
and greater overall work impairment (37.71% vs. 29.08%), among other variables 
(all p< .05). These relationships were not significant in the 5EU. ConClusions: A 
significant humanistic and economic burden of insomnia was observed in both the 
US and 5EU, and the burden remains even after treatment. Non-adherence due to 
side effects was common and, in the case of the US, associated with significantly 
poorer health outcomes.
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Quality Of life amONg PatieNts witH multiPle scleROsis tReateD 
witH PROlONgeD-Release famPRiDiNe 10 mg tablets fOR walkiNg 
imPaiRmeNt
Liu Y.1, McNeill M.2, Lee A.1, Zhong J.1, Mehta L.R.1
1Biogen Idec, Cambridge, MA, USA, 2Biogen Idec, Maidenhead, UK
objeCtives: To evaluate the effect of prolonged-release (PR) fampridine 10 mg 
tablet on generic quality of life (QoL) as measured by the EQ-5D in patients with 
multiple sclerosis (MS) with walking impairment. Methods: The study popula-
tion included 132 patients who enrolled in a 24-week randomized, double-blind, 
and placebo-controlled phase 2 trial (NCT01597297) of PR-fampridine 10 mg tab-
lets or placebo twice daily in multiple sites in Europe and Canada. Patients were 
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PeRsisteNce iN OPeN aND clOseD Data sOuRces: a stuDy Of fiNgOlimOD 
veRsus iNteRfeRONs/glatiRameR acetate iN PatieNts witH multiPle 
scleROsis
Lahoz R.1, Bergvall N.1, Nazareth T.2, Korn J.R.3
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharmaceuticals Corporation, East Hanover, 
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objeCtives: To compare 6-month persistence rates among patients receiving the 
multiple sclerosis (MS) disease-modifying therapies (DMTs) fingolimod or interferon/
glatiramer acetate (IFN/GA) (index DMT), using open- and closed-source data that 
reflect unrestricted or continuous health care coverage, respectively. Methods: 
Retrospective analyses used administrative claims and mail-order pharmacy data-
bases (IMS PharMetrics Plus™ [closed]) and LRx™ [open], respectively). All patients 
were ≥ 18 years old and naive to fingolimod and index DMT, had ≥ 1 prescription for 
index DMT between 01-Oct-2010 and 31-Mar-2013 and had not received multiple 
DMTs at index date. An additional PharMetrics cohort was selected using more 
stringent criteria (continuous enrolment pre-/post-index; MS diagnosis code). 
LRx prescriptions were collected from pharmacies supplying ≥ 1 claim for index 
DMT between the index date and the last month of follow-up. Persistence was 
defined as time from initiating index DMT until discontinuation (gap ≥ 60 days), 
receipt of another DMT or end of the 6-month follow-up period. Risk of and time 
to discontinuation were assessed by a Cox proportional hazards model (control-
ling for age, gender and region) and Kaplan-Meier analysis, respectively. Results: 
Using identical criteria, 22,467 PharMetrics patients (fingolimod: n= 1968; IFN/GA: 
n= 20,499) and 49,803 LRx patients (8325 and 41,478, respectively) were selected. 
Proportions of patients discontinuing index DMT were significantly lower for fin-
golimod vs IFN/GA (PharMetrics: 23.1% vs 27.2%; LRx: 26.9% vs 33.4%; p< 0.0001). Risk 
of discontinuation was higher for IFN/GA vs fingolimod (PharMetrics: hazard ratio, 
HR= 1.18; 95%CI: 1.07–1.30, p= 0.0008; LRx: HR= 1.23; 95%CI: 1.17–1.29, p< 0.0001). Time 
to discontinuation was significantly longer for fingolimod vs IFN/GA (PharMetrics: 
p= 0.0005; LRx: p< 0.0001). With more stringent criteria used in PharMetrics, risk 
of discontinuation of IFN/GA vs fingolimod increased (HR= 1.47; 95%CI: 1.24–1.74, 
p< 0.0001). ConClusions: Both data sources provided similar results, supporting 
use of open-source LRx data, which allows access to up-to-date information that 
can improve sample size and statistical power.
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cOmPaRisON Of tHe valuatiON Of tReatmeNt alteRNatives iN 
PaRkiNsON’s Disease witH best-wORst scaliNg, time tRaDe-Off aND 
visual aNalOgue scales
Weernink M.G.M.1, Groothuis-Oudshoorn C.G.M.1, IJzerman M.J.2, van Til J.A.1
1University of Twente, Enschede, The Netherlands, 2University of Twente and MIRA institute for 
Biomedical Technology & Technical Medicine, Enschede, The Netherlands
objeCtives: Traditional valuation methods are insensitive to small improvements 
in process and outcome of care. Best-Worst scaling (BWS) was proposed as a sensi-
tive and efficient method to determine the relative value of different treatments 
for the same disease, which would be desirable to estimate cost-effectiveness. The 
study objective was to compare the ability of BWS to differentiate between dif-
ferent treatment alternatives to that of Time Trade Off (TTO) and Visual Analogue 
Scales (VAS). Methods: An online survey was conducted to estimate individual 
values for six different treatments reflecting the real-life options in the treatment 
of Parkinson’s Disease with BWS2, BWS3, TTO and VAS (n= 592). Pearson correla-
tion coefficient was used to examine the strength of linear dependence between 
estimated utility scores. Results: Twenty-seven percent of respondents was not 
willing to trade life years in TTO. Only two percent of the respondent does not 
differentiate between the value of health states with VAS. When non-traders were 
excluded from the analysis, the best case scenario was valued significantly higher 
than the worst case scenario with all methods. Rank reversals among intermedi-
ate alternatives were common. The correlation between utility scores was very 
strong (VAS-BWS2 1,0; VAS-BWS3 0.98; TTO-BWS2 0.99; TTO-BWS3 0.98, BWS2-
BWS3 0.96; P< 0.000, n= 434). ConClusions: The results demonstrate that BWS, 
TTO and VAS can be used to elicit incremental utility gain of small improvements 
in care. However, all methods have limitations. VAS does not result in utilities 
and some respondents do not trade with TTO. While the use of BWS is attractive 
because of its ability to estimate utilities for many different treatment alterna-
tives, its applicability in CEA is limited because BWS utilities are not anchored on 
a 0-1 utility scale. We propose to use TTO to estimate utility for extreme health 
states, and to use BWS to value intermediate health states which differ on process 
characteristics.
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HealtH-RelateD Quality Of life iN migRaiNe witHOut auRa baseD ON 
attack fReQueNcy: a time tRaDe-Off stuDy
Rencz F.1, Brodszky V.1, Péntek M.1, Bereczki D.2, Gulacsi L.1
1Corvinus University of Budapest, Budapest, Hungary, 2Semmelweis University, Budapest, 
Hungary
objeCtives: To evaluate health-related quality of life (HRQOL) in migraine based 
on attack frequency by time trade-off method (TTO) in a mixed population sam-
ple consisting of migraneurs and non-migraneurs. Methods: A cross-sectional 
questionnaire survey was designed to measure HRQOL in migraine without aura 
by TTO. A convenience sample was recruited from university students and staff 
regardless of having ever experienced migraine or not. Participants were asked to 
elicit two hypothetical health states characterised by different migraine frequency 
(‘m’: two migraines lasting 4 hours each month and ‘w’: each week) within two 
hypothetical lifetime frames (20 years left to live/lives until the age of 80 years). 
Utilities were calculated for the four tasks (U20m, U80m, U20w, U20w) and com-
pared between subgroups. Results: Altogether 180 respondents were included 
in the analysis. Mean age was 25.6 years (SD 6.4), 71% were female and 61% were 
self-reported migraneurs. Proportion of non-traders varied between 14% and 43% 
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imPact Of caRegiviNg fOR PatieNts witH alzHeimeR’s Disease aND 
DemeNtia ON PsycHiatRic aND cliNical cOmORbiDities iN bRazil
Goren A.1, Novick D.2, Barros B.R.3, Laks J.4, Dueñas H.5, Kahle-Wrobleski K.6
1Kantar Health, New York, NY, USA, 2Eli Lilly and Company, Windlesham, UK, 3Eli Lilly do Brasil 
Ltda, São Paulo, Brazil, 4Federal University of Rio de Janeiro, Rio de Janeiro, Brazil, 5Eli Lilly de 
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objeCtives: Patients with dementia due to Alzheimer’s disease (AD) are often cared 
for by family members who experience physical, psychological, social, and financial 
burdens associated with provision of care. This study quantifies the impact of caregiv-
ing in Brazil and helps identify characteristics associated with caregiving. Methods: 
Data were analyzed from the 2012 National Health and Wellness Survey (NHWS) 
in Brazil (n = 12,000), an Internet-based survey of adults (aged 18+), using strati-
fied random sampling (by sex and age) to ensure demographic representation of the 
Brazil adult population. Caregivers were compared with non-caregivers on select 
comorbidities considered potential outcomes of caregiving, plus sociodemographic 
characteristics, health characteristics and behaviors, and Charlson comorbidity index 
(CCI) scores. Binary logistic regression models assessed comorbidities associated with 
caregiving, adjusting for potential confounds (CCI, age, gender, education, income, 
insurance, and marital status). Results: Among 10,853 respondents (caregivers 
[n= 209]; non-caregivers [n= 10,644]), caregivers were on average 42.1 years old, and 
53% were female, 52% married/living with a partner, 87% insured, and 42% living with 
1+ children in the household. Caregivers vs. non-caregivers were more frequently 
obese, smokers, insured, employed, and with college education or above, and they 
had higher CCI scores and higher income, all p < .05. Adjusting for covariates, caregiv-
ing was associated with significantly increased risk of depressive symptoms (odds 
ratio [OR] = 2.008), major depressive disorder (OR= 1.483), anxiety (OR= 1.714), insomnia 
(OR= 1.644), hypertension (OR= 1.584), pain (OR= 1.704), and diabetes (OR= 2.103), all 
p< .015. ConClusions: This is the first study on caregivers for persons with demen-
tia in Brazil using a large dataset (NHWS). Being a caregiver (compared with non-
caregiver) is a predictor of overall psychiatric and clinical disorders in this sample. The 
online survey format provides certain sampling advantages but may under-represent 
caregivers without access/comfort with online technology. Direct treatment and poli-
cies to help caregivers are needed in Brazil.
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cHOice exPeRimeNt aND cONtiNgeNt-valuatiON
Mühlbacher A.C.1, Johnson F.R.2, Yang J.C.3, Happich M.4
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objeCtives: Despite the existence of standardized medical criteria, clinical diagno-
sis of Alzheimer’s disease remains difficult. Lack of diagnostic certainty or possible 
distress related to positive results could limit application of new testing technolo-
gies. Independent of the therapeutic value of prevention or cure, however, diagnostic 
information could have value in informing contingency planning or have intrinsic 
value: the value of “just knowing”. This paper aims to quantify respondents’ prefer-
ences for obtaining AD diagnostic tests and to estimate the perceived value of AD 
test information. Methods: Discrete-choice experiment (DCE) and contingent-
valuation (CV) questions were administered to N= 1301 respondents aged 60 years 
or older in Germany and the United Kingdom. 12 pairs of virtual AD diagnostic tests 
were presented (defined by test type, test precision defined by false-positive or false-
negative test results, and test cost) and a no-test alternative. DCE questions were 
based on a predetermined experimental design. A double-bounded, dichotomous-
choice CV question was used to further elicit willingness to take an AD test and pay 
for it. Choice data of respondents interested in taking a test were analyzed using 
random-parameters logit. A probit model characterized respondents who were not 
willing to take a test. Results: Most respondents in both countries had a posi-
tive value for AD diagnostic test information. Most respondents who indicated an 
interest in testing in Germany (N= 631) and the UK (N= 670) preferred brain imaging 
without radioactive marker, followed by brain imaging with radioactive marker 
and then spinal tap. Diagnostic tests with better precision were preferred. German 
respondents had relatively greater heterogeneous preferences and lower money-
equivalent values for test features compared to UK respondents. ConClusions: 
Respondents preferred less invasive diagnostic procedures and tests with higher 
accuracy. Diagnostic test accuracy was more important than test type. Respondents 
expressed a willingness to pay up to € 700 to receive a less invasive test with the 
highest accuracy.
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tHe HumaNistic aND ecONOmic buRDeN Of PaRtial ONset seizuRes iN 
tHe euROPe five aND bRazil usiNg a PatieNt suRvey
Gupta S.1, Forsythe A.2, Pomerantz D.1, Tsong W.2
1Kantar Health, Princeton, NJ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA
objeCtives: The aim of this study was to understand the current impact of partial 
onset seizures (POS) on health outcomes and costs. Methods: Patients were identi-
fied from the 2010 & 2013 5EU and 2011-2012 Brazil National Health and Wellness 
Survey, a nationally represented, internet-based survey of adults (18+ years). 
Patients self-reported a diagnosis of epilepsy with POS and were categorized into 
≥ 1 seizure per week, 1-3 seizures per month, 1-4 seizures per year, < 1 seizure per 
year (reference). Patients completed the SF-36v2 (mental (MCS), physical component 
summary (PCS)), SF-6D (health utility), Work Productivity and Activity Impairment 
Questionnaire and reported on resource utilization in the past six months. Costs 
were estimated from the literature. Generalized linear regression analyses were 
conducted controlling for covariates (e. g., age, gender, marital status, comorbidities, 
years diagnosed with epilepsy). Results: There were 175 patients in the 5EU and 
32 in Brazil, 11.1% reported ≥ 1 seizures/week, 7.7% reported 1-3 seizures/month, 
26.1% 1-4 seizures/year, and 55.1% < 1seizures/year. MCS, PCS, utilities, productivity 
categorized into three groups: placebo, PR-fampridine responders (those with 
a mean improvement from baseline in the 12-item MS walking scale [MSWS-
12] of ≥ 8 points over 24 weeks), and PR-fampridine nonresponders (those with 
worsening, no change, or < 8 points improvement in MSWS-12). Changes from 
baseline were calculated for the EQ-5D utility index and visual analogue scale 
(VAS) by visit and over the 24 weeks. Within-group and pairwise comparisons 
were assessed based on the least square (LS) means using analysis of covariance 
(ANCOVA) models adjusting for baseline EQ-5D scores. Results: The placebo 
patients (n= 64), responders (n= 33), and nonresponders (n= 35) were similar in 
baseline age, race, weight, and number of relapses in the past 1 and 2 years. 
The responders had higher mean baseline EQ-5D utility (0.56 vs. 0.51 and 0.52, 
respectively) and VAS (62.9 vs. 59.1 and 60.5, respectively) scores than the placebo 
patients and nonresponders. Over the 24 weeks, the EQ-5D utility score improved 
in the responders (mean change: 0.06, 95% CI: [0.01, 0.12]) but worsened in the 
placebo patients (mean change: -0.03,95% CI: [-0.07, 0.01]) and nonresponders 
(mean change: -0.07,95% CI: [-0.12, -0.02] ). Similar trends were observed in the VAS 
scores although the differences within groups were generally not statistically sig-
nificant. ConClusions: PR-fampridine 10 mg tablets demonstrated significantly 
greater improvement in QoL among responders, despite starting from higher base-
line EQ-5D scores, than the placebo or nonresponder groups.
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tHe buRDeN Of PRimaRy geNeRalizeD tONic-clONic seizuRes iN euROPe 
aND tHe uNiteD states: aN aNalysis Of tHe NatiONal HealtH aND 
wellNess suRvey
Gupta S.1, Forsythe A.2, Pomerantz D.1, Tsong W.2
1Kantar Health, Princeton, NJ, USA, 2Eisai Inc., Woodcliff Lake, NJ, USA
objeCtives: Many prescription medications are available to treat Primary 
Generalized Tonic-Clonic (PGTC) seizures. The objective is to understand the 
impact of PGTC on health outcomes. Methods: Data from the 2011-2013 U.S. and 
2010 & 2013 5E.U. National Health and Wellness Survey (NHWS) were analyzed. 
The NHWS is self-administered, internet-based survey of a nationwide sample of 
adults (18+ years) stratified to represent the demographic composition of each 
country. Patients self-reported a diagnosis of epilepsy with PGTC and were grouped 
as ≥ 1 seizure per week, 1-3 seizures per month, 1-4 seizures per year, < 1 seizure 
per year (reference). Patients provided information on health status (mental (MCS), 
physical component summary (PCS), and SF-6D (health utility) from the SF-36v2), 
resource utilization in the past six months and productivity loss (Work Productivity 
and Activity Impairment Questionnaire). Costs were estimated from the literature. 
Regression analyses were conducted controlling for covariates (e. g., age, gender, 
marital status, comorbidities, years diagnosed with epilepsy). Results: There were 
782 patients in the U.S. and 418 in the 5EU. In both geographies the proportion of 
employed respondents decreased as frequency of seizures increased. Over 75% of 
patients in both geographies were taking a prescription medication for epilepsy. 
After adjustments, patients reporting < 1 seizure per year had greater PCS, health 
utilities, lower activity impairment, fewer emergency room visits and lower total 
direct costs compared to the other three seizure groups (p< 0.05 both geographies). 
Among employed patients, patients reporting < 1 seizure per year had the lowest 
overall work impairment (p< 0.05 both geographies). For all employable patients 
(18-60 years) indirect costs were highest for the ≥ 1 seizure per week group (p< 0.05 
both geographies). ConClusions: Results suggest a significantly higher economic 
and humanistic burden in patients with more frequent seizures. PGTC patients are 
very much in need of newer treatment options.
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factORs assOciateD witH caRegiveR’s buRDeN iN RelaPsiNg-RemittiNg 
multiPle scleROsis aND satisfactiON witH cuRReNt tHeRaPies.  
ms-feeliNg stuDy
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1Novartis Farmaceutica, Barcelona, Spain, 2TFS Develop S.A., Barcelona, Spain, 3Hospital Virgen 
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objeCtives: To describe the characteristics and burden of caregivers and patients 
affected by relapsing-remitting multiple sclerosis (RRMS), and to describe their sat-
isfaction with treatment. Methods: Multicenter, observational, cross-sectional 
study in RRMS patients≥ 18 years (y), treated for ≥ 1y. Burden was assessed with 
the Zarit Burden Interview. Other measures were: Center for Epidemiologic Studies 
Depression Scale, short form (CESD-7); and treatment satisfaction of caregivers (ad-
hoc questionnaire) and patients (Treatment Satisfaction Questionnaire for Medication 
(TSQM)). Results: We included 180 patients (mean (SD) age 41 (11) y, 66% female) and 
caregivers (47 (12) y, 56% female, 67% economically active). Most caregivers were rela-
tives (59% partner; 25% parent; 9% brother or sister) and lived with the patient (86%); 
37% helped with the medication. Median (Q1, Q3) time since diagnosis was 7 (4,10) y 
and between diagnosis and first treatment, 0.3 (0.2, 1.3) y. Most patients received 
monotherapy with interferon beta (51%), glatiramer acetate (20%), natalizumab (14%) 
or fingolimod (7%); 15.6% received ≥ 2 drugs. Median EDSS was 2.5 (1,4). According to 
the Zarit Interview, 19% of caregivers had some degree of burden (median: 10 (7,15)). 
Factors associated with burden were: EDSS (mean (SD) in caregivers with burden vs 
without burden, respectively: 4.0 (2.1) vs 2.6 (1.9), p< 0.0005), years of caregiving (mean: 
4.0 (4.5) vs 2.7 (4.5) y, p= 0.005), daily hours dedicated to patient (10.8 (12.1) vs 5.8 (4.6) 
hours, p= 0.038), and > 1 drug (39% of burden when patients take≥ 2 drugs vs 16% with 
monotherapy, p= 0.004). Other caregiver’s characteristics (age, gender, professional 
activity, relationship with patient or cohabitation) were not significantly associated. 
28.2% of caregivers had depression (CESD-7≥ 15). Both patients (90% satisfied or very 
satisfied according to the TSQM) and caregivers (mean of 7.6 (2.3) on a scale from 
0-10 [maximum satisfaction]) were quite satisfied with treatment. ConClusions: 
In the RRMS population with moderate disability, around 2 in 10 caregivers have some 
degree of burden, and 1 in 4 suffer depression. The burden increases proportionately 
with disease severity and number of medications administered. Overall, patients and 
caregivers are satisfied with treatment.
